Search Results for 'Biosimilars'

---

Contract Service Directory Companies

View All Buyers Guide Companies »

---

Contract Service Directory Categories

View All Categories »

---

• Bio News | Biosimilars | Breaking News | Collaborations & Alliances | Industry News
  

  Sandoz Enters Biosimilars Deal with Gan & Lee Pharmaceutical in China

  Covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart

  12.28.18
  

  ---

• Biosimilars
  

  Biosimilar Market Trends

  2017 was a record year for biosimilar approvals.

  Fiona Greer and Bruno Speder, SGS 09.11.18
  

  ---

• Bio News | Biosimilars
  

  Know the Challenges of Biosimilar Manufacturing

  Best Practices for a Competitive Market

  Jerry Martin, Pharmaceutical and Life Sciences Consultant to PMMI, and, Dr. Michiel Ultee, Principal, Ulteemit BioConsulting, LLC 04.11.18
  

  ---

• Biosimilars
  

  Indian Generic Firms Expand Biosimilar Portfolios

  With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India

  S. Harachand, Contributing Editor 05.09.17
  

  ---

• Biosimilars
  

  CMOs & Biosimilars Mfg. in the U.S.

  Biosimilars are moving from novel opportunity to mainstream product

  Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17
  

  ---

• Biosimilars | Clinical Trials | Process Development
  

  Biosimilars Outsourcing and Capacity

  CMOs to play important but uncertain role in biosimilars manufacturing

  Ronald A. Rader and Eric S. Langer, BioPlan Associates 05.05.16
  

  ---

• Biosimilars | Clinical Trials | Risk Management
  

  Growth of Biosimilars: Implications for Safety and Risk Management

  Global biologics market will expand to $250 billion annually by 2020, with biosimilars and non-original biologics commanding 4-10% of that market

  Suhasini Sharma, Sciformix Corporation 09.11.15
  

  ---

• Biosimilars

  Biosimilars and Biobetters: From Basic Similarity to Simplified Innovation

  Everyone talks about biosimilarity, but it’s clarifying the differences between biosimilars, biobetters and me-too products that will be critical to biological innovation and pricing

  Fereshteh Barei, Dauphine University 06.18.14
  

  ---

• Biosimilars

  Unlocking the Potential of Biosimilars

  Biosimilars face far more demanding clinical, market access, manufacturing and sales and marketing requirements, than small-molecule generics did.

  Gurpreet Sandhu, Reva Pharmaceuticals 06.18.14
  

  ---